Why the study?
The study aimed to evaluate ACE, ACE2, and inflammatory mediators that have emerged as significant indicators of cardiovascular risk and mortality.
Are plasma ACE, ACE2, and inflammatory markers associated with coronary heart disease in patients with type 2 diabetes mellitus?
Observational (n=261)
Are plasma ACE, ACE2, and inflammatory markers associated with coronary heart disease in patients with type 2 diabetes mellitus?
Plasma ACE, ACE2, and inflammatory mediators are significantly elevated in T2DM patients with CHD, suggesting their potential utility in cardiovascular risk assessment.
Answers are grounded in this paper and cite their sources.
Elevated ACE, ACE2, and inflammatory markers associate with CHD in T2DM; hypothesis-generating for risk stratification.
Objective Angiotensin-converting enzyme (ACE) and Angiotensin-converting enzyme 2 (ACE2) are a Renin Angiotensin System (RAS) enzyme highly expressed in the lung, kidney, heart and pancreas. The study aim to identify ACE, ACE2, along with inflammatory mediators that have emerged as significant indicators of cardiovascular risk and mortality. Material and Methods A total of 261 study participants were stratified into three groups. Each group has 87 individuals. Group 1: healthy controls, Group 2: Type 2 Diabetes Mellitus (T2DM), and Group 3: Type 2 Diabetes Mellitus with Coronary Heart Disease (CHD). All participants underwent a comprehensive health evaluation at the cardiology and internal medicine outpatient clinics. Plasma concentrations of ACE, ACE2, Interleukin-6 (IL-6), and Tumor Necrosis Factor -α (TNF-α) were quantified using ELISA. Lipid profiles were assessed using the AU480 analyzer (Beckman Coulter, Inc.). Results This research indicated that the circulating concentration of ACE, ACE2, ACE/ACE2 ratio, IL-6, and TNF-α levels were significantly elevated in T2DM with CHD than compared to controls (p-value < 0.01). ACE, ACE2, ACE/ACE2 ratio, IL-6, and TNF-α were shown to be significantly correlated in individuals with T2DM with CHD. Conclusion The study concludes that plasma ACE, ACE2 and inflammatory mediators correlate with an elevated risk of cardiovascular illness in T2DM, particularly in individuals with CHD. The present findings indicate that tailored risk assessment could benefit individuals with diabetes.
No takes yet. Share an insight, caveat, or question.
Naveena et al. (2025) conducted an observational in Type 2 Diabetes Mellitus with and without Coronary Heart Disease (n=261).
Synapse has enriched 10 related papers. Consider them for comparative context: